Screening for Colorectal Cancer

Overview

Journal Hematol Oncol Clin North Am

Specialties Hematology
Oncology

Date 2022 May 2

PMID 35501176

Authors

Samir Gupta

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) is the second-leading cause of cancer death in the United States. Screening reduces CRC incidence and mortality. 2021 US Preventive Service Task Force (USPSTF) guidelines and available evidence support routine screening from ages 45 to 75, and individualized consideration of screening ages 76 to 85. USPSTF guidelines recommend annual guaiac fecal occult blood testing, annual fecal immunochemical testing (FIT), annual to every 3-year multitarget stool DNA-FIT, every 5-year sigmoidoscopy, every 10-year sigmoidoscopy with annual FIT, every 5-year computed tomographic colonography, and every 10-year colonoscopy as options for screening. The "best test is the one that gets done."

Citing Articles

Value of brief hematological characteristics in differentiating carcinoembryonic-antigen-negative colorectal cancer from benign colorectal diseases.

Yi L, Lao X, Lu L, Zhu C, Zhou D, Li S World J Gastrointest Surg. 2025; 17(2):101403.

PMID: 40061991 PMC: 11885996. DOI: 10.4240/wjgs.v17.i2.101403.

Screening for Colorectal Carcinoma in India: Real-World Scenario, Pitfalls, and Solutions.

Agrawal M, Surendran A, Venkatesh K, Velammal P, Zope S, Goel A South Asian J Cancer. 2025; 13(4):229-235.

PMID: 40060340 PMC: 11888814. DOI: 10.1055/s-0045-1802655.

Disparities in Cancer Screening Among the Foreign-Born Population in the United States: A Narrative Review.

Rosowicz A, Hewitt D Cancers (Basel). 2025; 17(4).

PMID: 40002170 PMC: 11852454. DOI: 10.3390/cancers17040576.

L. Extract Inhibits Colorectal Cancer Tumor Growth by Modulating Cell Apoptosis and Autophagy.

Tsai M, Chen C, Chen C, Lee M, Wu L, Hsu Y Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996849 PMC: 11854706. DOI: 10.3390/cimb47020128.

Re-screening adherence to multi-target stool DNA test for colorectal cancer: real-world study in a large national population.

Greene M, Pew T, Dore M, Ebner D, Ozbay A, Johnson W Int J Colorectal Dis. 2025; 40(1):48.

PMID: 39992481 PMC: 11850584. DOI: 10.1007/s00384-025-04837-6.

References

Meester R, van Herk M, Lansdorp-Vogelaar I, Ladabaum U . Prevalence and Clinical Features of Sessile Serrated Polyps: A Systematic Review. Gastroenterology. 2020; 159(1):105-118.e25. PMC: 8653879. DOI: 10.1053/j.gastro.2020.03.025. View

Tsuji Y, Gunji T, Sato H, Ono A, Ito T, Ohata K . Antithrombotic drug does not affect the positive predictive value of an immunochemical fecal occult blood test. Dig Endosc. 2013; 26(3):424-9. DOI: 10.1111/den.12208. View

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

Niikura R, Yamada A, Fujishiro M, Tanaka K, Matsuda K, Saito Y . The Effects of Direct Oral Anticoagulants, Warfarin, Aspirin and Thienopyridine on the Performance of Immunochemical, Faecal, Occult Blood Tests. Digestion. 2018; 100(2):117-126. DOI: 10.1159/000494251. View

Ibuka T, Adachi S, Horibe Y, Ohno T, Mabuchi M, Suzuki Y . Effects of antithrombotic drugs on the results of fecal immunochemical test in colorectal neoplasms screening. Sci Rep. 2021; 11(1):4348. PMC: 7902607. DOI: 10.1038/s41598-021-83007-4. View

Bailie L, Loughrey M, Coleman H . Lifestyle Risk Factors for Serrated Colorectal Polyps: A Systematic Review and Meta-analysis. Gastroenterology. 2016; 152(1):92-104. DOI: 10.1053/j.gastro.2016.09.003. View

Holme O, Loberg M, Kalager M, Bretthauer M, Hernan M, Aas E . Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. 2014; 312(6):606-15. PMC: 4495882. DOI: 10.1001/jama.2014.8266. View

Dougherty M, Brenner A, Crockett S, Gupta S, Wheeler S, Coker-Schwimmer M . Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States: A Systematic Review and Meta-analysis. JAMA Intern Med. 2018; 178(12):1645-1658. PMC: 6583619. DOI: 10.1001/jamainternmed.2018.4637. View

Levin T, Corley D, Jensen C, Schottinger J, Quinn V, Zauber A . Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology. 2018; 155(5):1383-1391.e5. PMC: 6240353. DOI: 10.1053/j.gastro.2018.07.017. View

10.

Murthy S, Feuerstein J, Nguyen G, Velayos F . AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology. 2021; 161(3):1043-1051.e4. DOI: 10.1053/j.gastro.2021.05.063. View

11.

May F, Yang L, Corona E, Glenn B, Bastani R . Disparities in Colorectal Cancer Screening in the United States Before and After Implementation of the Affordable Care Act. Clin Gastroenterol Hepatol. 2019; 18(8):1796-1804.e2. DOI: 10.1016/j.cgh.2019.09.008. View

12.

Kahi C, Imperiale T, Juliar B, Rex D . Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol. 2009; 7(7):770-5. DOI: 10.1016/j.cgh.2008.12.030. View

13.

Lin J, Perdue L, Henrikson N, Bean S, Blasi P . Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021; 325(19):1978-1998. DOI: 10.1001/jama.2021.4417. View

14.

Fitzpatrick-Lewis D, Ali M, Warren R, Kenny M, Sherifali D, Raina P . Screening for Colorectal Cancer: A Systematic Review and Meta-Analysis. Clin Colorectal Cancer. 2016; 15(4):298-313. DOI: 10.1016/j.clcc.2016.03.003. View

15.

Rossi P, Vicentini M, Sacchettini C, Di Felice E, Caroli S, Ferrari F . Impact of Screening Program on Incidence of Colorectal Cancer: A Cohort Study in Italy. Am J Gastroenterol. 2015; 110(9):1359-66. DOI: 10.1038/ajg.2015.240. View

16.

Brenner H, Altenhofen L, Stock C, Hoffmeister M . Incidence of colorectal adenomas: birth cohort analysis among 4.3 million participants of screening colonoscopy. Cancer Epidemiol Biomarkers Prev. 2014; 23(9):1920-7. DOI: 10.1158/1055-9965.EPI-14-0367. View

17.

Eldridge R, Doubeni C, Fletcher R, Zauber A, Corley D, Doria-Rose V . Uncontrolled confounding in studies of screening effectiveness: an example of colonoscopy. J Med Screen. 2013; 20(4):198-207. PMC: 3923570. DOI: 10.1177/0969141313508282. View

18.

Tinmouth J, Vella E, Baxter N, Dube C, Gould M, Hey A . Colorectal Cancer Screening in Average Risk Populations: Evidence Summary. Can J Gastroenterol Hepatol. 2016; 2016:2878149. PMC: 5002289. DOI: 10.1155/2016/2878149. View

19.

Selby K, Jensen C, Zhao W, Lee J, Slam A, Schottinger J . Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study. Clin Transl Gastroenterol. 2019; 10(2):e00010. PMC: 6407828. DOI: 10.14309/ctg.0000000000000010. View

20.

Ventura L, Mantellini P, Grazzini G, Castiglione G, Buzzoni C, Rubeca T . The impact of immunochemical faecal occult blood testing on colorectal cancer incidence. Dig Liver Dis. 2013; 46(1):82-6. DOI: 10.1016/j.dld.2013.07.017. View